Aldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 6, 2015, Pages 6901-6909

  Chen, Wei Guo ^a   Zhou, Ting Ting ^a   Zhou, Peng ^a   Li, Xiao Wei ^a   Wu, Zhun ^b   Zhang, Kai Yan ^b   Xing, Jin Chun ^b  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Aldosterone to renin ratio (ARR); Chronic kidney disease; Primary aldosteronism; Receiver operating characteristic (ROC) curve

Indexed keywords

ALDOSTERONE; BIOLOGICAL MARKER; RENIN;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; BLOOD; CHILD; CHINA; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HYPERALDOSTERONISM; MALE; MIDDLE AGED; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE; AREA UNDER CURVE; BIOMARKERS; CHILD; CHINA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERALDOSTERONISM; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, CHRONIC; RENIN; RETROSPECTIVE STUDIES; ROC CURVE; YOUNG ADULT;

EID: 84938631795     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Conn JW, Knopf RF, Nesbit RM. Clinical Characteristics of Primary Aldosteronism from an Analysis of 145 Cases. Am J Surg 1964; 107: 159-172.
2. Takahashi S, Yoshida E, Sakanishi Y, Tohyama N, Ayhan A, Ogawa H. Congenital multiple intrahepatic portosystemic shunt: an autopsy case. Int J Clin Exp Pathol 2013; 7: 425-431.
3. Rossi GP. Diagnosis and treatment of primary aldosteronism. Endocrinol Metab Clin North Am 2011; 40: 313-332.
4. Stowasser M, Gordon RD. Primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2003; 17: 591-605.
5. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281.
6. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896.
7. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A,Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921-1926.
8. Schmiemann G, Gebhardt K, Hummers-Pradier E, Egidi G. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med 2012; 25: 98-103.
9. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248.
10. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 2009; 94: 1125-1130.
11. Nishimura M, Uzu T, Fujii T, Kuroda S, Naka-mura S. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261-266.
12. Young WF. Primary aldosteronism-treatment options. Growth Horm IGF Res 2003; 13: 102-108.
13. Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C,Corgnati A, Falcone S, Corrocher R, Micchi A, Cressoni C, Blengio G. Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004; 89: 4221-4226.
14. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, O'Donnell CJ, Musone SL, Camargo AL, Drake JA, Levy D, Hirschhorn JN, Vasan RS. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49: 846-856.
15. Montori VM, Schwartz GL, Chapman AB, Boer-winkle E, Turner ST. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001; 76: 877-882.
16. Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, Kong AP. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 2005; 90: 72-78.
17. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma rennin activity ratio and in primary aldosteronism. Hypertension 2002; 40: 897-902.
18. Kaplan NM. The current epidemic of primary aldosteronism: cause and Consequence J. Hypertens 2004; 22: 863-869.
19. Lamarre-Cliché M, de Champlain J, Lacourciere Y. Effects of circadiam rhythms, posture, and medication on rennin-aldosterone interrelation in essential hypertensive. Am J hypertens 2005; 18: 56-64.
20. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab 2009; 94: 3623-3630.
21. Terata S, Kikuya M, Satoh M, Ohkubo T, Hashimoto T, Hara A, Hirose T, Obara T, Metoki H, Inoue R, Asayama K, Kanno A, Totsune K, Hoshi H, Satoh H, Sato H, Imai Y. Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama Study. J Hypertens 2012; 30: 1632-1638.
22. Kotliar C, Inserra F, Forcada P, Cavanagh E, Obregon S, Navari C, Castellaro C, Sánchez R. Are plasma renin activity and aldosterone levels useful as a screening test to differentiate between unilateral and bilateral renal artery stenosis in hypertensive patients? J Hypertens 2010; 28: 594-601.
23. Lingam RK, Sohaib SA, Vlahos I, Rockall AG, Isidori AM, Monson JP, Grossman A, Reznek RH. CT of primary hyperaldosteronism (Conn's syndrome): the value of measuring the adrenal gland. AJR Am J Roentgenol 2003; 181: 843-849.
24. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, O'Donnell CJ, Musone SL, Camargo AL, Drake JA, Levy D, Hirschhorn JN, Vasan RS. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49: 846-856.
25. Auchus RJ, Wians FH, Anderson ME, Dolmatch BL, Trimmer CK, Josephs SC. What we still do not konow about adrenal vein sampling in primary aldosteronism. Horm Metab Res 2010; 42: 411-415.
26. Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ. Amultimarker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol 2010; 21: 2143-2149.
27. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112.
28. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93: 990-996.
29. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 542-551.
30. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045-1050.
31. Wu Z, Ni D, Yan Y, Li J, Wang B, Ouyang J, Zhang G, Ma X, Li H, Zhang X. Expression of angiotensin II receptors in aldosterone-producing adenoma of the adrenal gland and their clinical significance. J Huazhong Univ Sci Technolog Med Sci 2010; 30: 486-489.
32. Ouyang J, Wu Z, Xing J, Yan Y, Zhang G, Wang B, Li H, Ma X, Zhang X. Association of polymorphisms in angiotensin II receptor genes with aldosterone-producing adenoma. J Huazhong Univ Sci Technolog Med Sci 2011; 1: 301-305.
33. Saha S, Willenberg HS, Bornstein SR, Graessler J, Kopprasch S. Diabetic lipoproteins and adrenal aldosterone synthesis--a possible pathophysiological link? Horm Metab Res 2012; 44: 239-244.
34. Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009; 53: 605-610.
35. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66: 607-608.
36. Chen C, Zhou X, Jing J, Cheng J, Luo Y, Chen J, Xu X, Leng F, Li X, Lu Z. Decreased LINE-1 methylation levels in aldosterone-producing adenoma. Int J Clin Exp Pathol 2014; 7: 4104-4111.